View Future GrowthPerk Labs 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Perk Labs 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Software 산업 성장률17.33%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Aug 2023최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 14Perk Labs Inc. announced that it expects to receive CAD 2.5 million in fundingPerk Labs Inc. announced a non-brokered private placements of units and convertible debentures on June 12, 2024. The Company is proposing a new non-brokered private placement of up to 115,384,615 units at a price of CAD 0.013 per Unit for gross proceeds of up to CAD 1,499,999.995 and convertible debentures for gross proceeds of up to CAD 1,000,000; aggregate gross proceeds of CAD 2,499,999.995. Each Unit will consist of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the Closing. The convertible debentures will be offered for a 2-year term at an interest rate of 15% and will be convertible into common shares of Perk Labs at a conversion price of CAD 0.05 per share. The private placements of the Units and the convertible debentures are expected to close on or before June 29, 2024. The Closing is subject to customary closing conditions, including, but not limited to, the receipt of all necessary approvals. All securities issued pursuant to the private placements will be subject to a statutory hold period of four months and one day following the Closing. A finder’s fee may be payable in connection with the Private Placements.공시 • Apr 26Perk Labs Inc. announced that it has received CAD 1.714 million in fundingOn April 25, 2024, Perk Labs Inc. closed the transaction. The company announced that it has issued 78,900,000 units at a price of CAD 0.01 per unit for the gross proceeds of CAD 789,000 and 15% convertible debentures for the gross proceeds of CAD 25,000; aggregate gross proceeds of CAD 814,000 in third and final tranche. Each Unit consists of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the closing. The Debentures mature two years from the date of issuance and bear interest at a rate of 15% per annum. The Debentures are convertible into Common Shares at a conversion price of CAD 0.05 per Common Share, subject to the terms and conditions set forth in the specific Debenture agreement. All securities issued pursuant to the private placements are subject to a statutory hold period of four months and one day following the closing. In connection with private placements, B. Rogic acquired CAD 73,000 of Units공시 • Dec 14+ 1 more updatePerk Labs Inc. Announces Issuance of U.S. PatentPerk Labs Inc. announced the issuance of its United States patent that protects the Company's rights to one of its inventions for systems and methods for electronic payments with fraud prevention, based on correlating transaction data and information from a user's device.공시 • Sep 29Perk Labs Inc. announced that it has received CAD 0.471 million in fundingOn September 28, 2023, Perk Labs Inc. closed the transaction. The company issued 1,312,500 units at an issue price of CAD 0.016 per unit for the gross proceeds of CAD 21,000 and convertible debentures for the gross proceeds of CAD 450,000; aggregate gross proceeds of CAD 471,000. Each Unit consists of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the closing. The Debentures mature one year from the date of issuance and bear interest at a rate of 15% per annum. The Debentures are convertible into Common Shares at a conversion price of CAD 0.05 per Common Share. All securities issued pursuant to the private placements are subject to a statutory hold period of four months and one day following the closing. The bonds will mature on September 28, 2024.공시 • Jul 15+ 1 more updatePerk Labs Inc. announced that it expects to receive CAD 0.35 million in fundingPerk Labs Inc. announced a non-brokered private placement of 6,250,000 units at an issue price of CAD 0.016 per unit for the gross proceeds of up to CAD 100,000 and convertible debentures for the gross proceeds of CAD 250,000, for the aggregate gross proceeds of CAD 350,000 on July 14, 2023. Each Unit will consist of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per common share for a period of 24 months from the Closing. The convertible debentures will be offered on varying terms, including interest rates ranging from 5% to 15% and differing acceleration terms and maturity dates specific to the terms of each convertible debenture agreement. The convertible debentures will be convertible into common shares of Perk Labs at a conversion price of CAD 0.05 per share, subject to the terms and conditions set forth in the specific convertible debenture agreement. The Closing is subject to customary closing conditions, including, but not limited to, the receipt of all necessary approvals. All securities issued pursuant to the private placement will be subject to a statutory hold period of four months and one day following the Closing. The private placement of the Units and the convertible debentures is expected to close on or before August 24, 2023.공시 • Jul 10Perk Labs Inc. Announces Patrick Power Resigns from BoardPerk Labs Inc. at its Annual General Meeting of Shareholders held on July 5, 2023, announced Patrick Power has submitted his resignation to the Board. After review and consideration, the Board has accepted Mr. Power's resignation.공시 • May 25Perk Labs Inc., Annual General Meeting, Jul 05, 2023Perk Labs Inc., Annual General Meeting, Jul 05, 2023.공시 • Jan 21Perk Labs Inc. Announces CFO TransitionPerk Labs Inc. announced that effective February 17, 2023, Andrew Bailes, a seasoned finance executive, will succeed Ms. Altamirano as Interim CFO until a permanent CFO is named. Vanessa Altamirano will step down effective February 17, 2023 to pursue another professional opportunity. Perk is currently in the process of structuring a merger with Getit Technologies Inc. (‘Getit’), and as part of the process, the Company continues to review its team to optimise the integration of the two companies. Andrew Bailes is a Chartered Public Accountant, Principal at Hertford Advisors and has served in CFO roles since 2006. He has extensive experience in IT, Telecoms, Logistics, manufacturing and other sectors, managing finance and Legal, HR and Operational functions. Andrew did his undergraduate degree in Mathematics and Management Studies at Cambridge University in the UK and was top in his Executive MBA at Cornell and Queens. His notable achievements include: CFO for various capital raises totaling over $100 million Negotiation of many multi-million dollar debt facilities Head of a 25-man Finance Department at one of Ottawa's larger production facilities Twenty-five years' experience in Business and Strategic planning .공시 • Jan 05Perk Labs Inc. Appoints Patrick Power to the Board of DirectorsPerk Labs Inc. announced that it has appointed Mr. Patrick Power to the company's board of directors, effective immediately. Mr. Power brings a wealth of experience in business and finance to the board. He is the Chairman and President of James Edward Capital Corporation, an Ottawa-based boutique investment bank focused on emerging growth companies and is advising the Company on its strategic options. Mr. Power has significant experience in finance and governance, having previously served in senior executive roles for several TSX/TSXV-listed technology companies.매출 및 비용 세부 내역Perk Labs가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:PKLB.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Aug 230-21131 May 230-21128 Feb 230-31130 Nov 220-32131 Aug 220-32131 May 220-42128 Feb 220-42130 Nov 210-12131 Aug 210-23131 May 210-23128 Feb 210-23130 Nov 200-42131 Aug 200-50331 May 200-80329 Feb 200-143330 Nov 190-84331 Aug 190-610-231 May 191-611-128 Feb 191-311030 Nov 182-1314031 Aug 182-1816231 May 182-1716128 Feb 182-1413130 Nov 171-109131 Aug 170-54131 May 170-43028 Feb 170-32030 Nov 160-22031 Aug 160-11031 May 160-11029 Feb 160-100양질의 수익: PKLB.F가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 PKLB.F의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 PKLB.F의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: PKLB.F의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: PKLB.F의 지난 해 수익 증가율이 Software 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: PKLB.F는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YSoftware 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/19 01:56종가2026/05/12 00:00수익2023/08/31연간 수익2022/11/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Perk Labs Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jun 14Perk Labs Inc. announced that it expects to receive CAD 2.5 million in fundingPerk Labs Inc. announced a non-brokered private placements of units and convertible debentures on June 12, 2024. The Company is proposing a new non-brokered private placement of up to 115,384,615 units at a price of CAD 0.013 per Unit for gross proceeds of up to CAD 1,499,999.995 and convertible debentures for gross proceeds of up to CAD 1,000,000; aggregate gross proceeds of CAD 2,499,999.995. Each Unit will consist of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the Closing. The convertible debentures will be offered for a 2-year term at an interest rate of 15% and will be convertible into common shares of Perk Labs at a conversion price of CAD 0.05 per share. The private placements of the Units and the convertible debentures are expected to close on or before June 29, 2024. The Closing is subject to customary closing conditions, including, but not limited to, the receipt of all necessary approvals. All securities issued pursuant to the private placements will be subject to a statutory hold period of four months and one day following the Closing. A finder’s fee may be payable in connection with the Private Placements.
공시 • Apr 26Perk Labs Inc. announced that it has received CAD 1.714 million in fundingOn April 25, 2024, Perk Labs Inc. closed the transaction. The company announced that it has issued 78,900,000 units at a price of CAD 0.01 per unit for the gross proceeds of CAD 789,000 and 15% convertible debentures for the gross proceeds of CAD 25,000; aggregate gross proceeds of CAD 814,000 in third and final tranche. Each Unit consists of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the closing. The Debentures mature two years from the date of issuance and bear interest at a rate of 15% per annum. The Debentures are convertible into Common Shares at a conversion price of CAD 0.05 per Common Share, subject to the terms and conditions set forth in the specific Debenture agreement. All securities issued pursuant to the private placements are subject to a statutory hold period of four months and one day following the closing. In connection with private placements, B. Rogic acquired CAD 73,000 of Units
공시 • Dec 14+ 1 more updatePerk Labs Inc. Announces Issuance of U.S. PatentPerk Labs Inc. announced the issuance of its United States patent that protects the Company's rights to one of its inventions for systems and methods for electronic payments with fraud prevention, based on correlating transaction data and information from a user's device.
공시 • Sep 29Perk Labs Inc. announced that it has received CAD 0.471 million in fundingOn September 28, 2023, Perk Labs Inc. closed the transaction. The company issued 1,312,500 units at an issue price of CAD 0.016 per unit for the gross proceeds of CAD 21,000 and convertible debentures for the gross proceeds of CAD 450,000; aggregate gross proceeds of CAD 471,000. Each Unit consists of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per Common Share for a period of 24 months from the closing. The Debentures mature one year from the date of issuance and bear interest at a rate of 15% per annum. The Debentures are convertible into Common Shares at a conversion price of CAD 0.05 per Common Share. All securities issued pursuant to the private placements are subject to a statutory hold period of four months and one day following the closing. The bonds will mature on September 28, 2024.
공시 • Jul 15+ 1 more updatePerk Labs Inc. announced that it expects to receive CAD 0.35 million in fundingPerk Labs Inc. announced a non-brokered private placement of 6,250,000 units at an issue price of CAD 0.016 per unit for the gross proceeds of up to CAD 100,000 and convertible debentures for the gross proceeds of CAD 250,000, for the aggregate gross proceeds of CAD 350,000 on July 14, 2023. Each Unit will consist of one common share and one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at a price of CAD 0.05 per common share for a period of 24 months from the Closing. The convertible debentures will be offered on varying terms, including interest rates ranging from 5% to 15% and differing acceleration terms and maturity dates specific to the terms of each convertible debenture agreement. The convertible debentures will be convertible into common shares of Perk Labs at a conversion price of CAD 0.05 per share, subject to the terms and conditions set forth in the specific convertible debenture agreement. The Closing is subject to customary closing conditions, including, but not limited to, the receipt of all necessary approvals. All securities issued pursuant to the private placement will be subject to a statutory hold period of four months and one day following the Closing. The private placement of the Units and the convertible debentures is expected to close on or before August 24, 2023.
공시 • Jul 10Perk Labs Inc. Announces Patrick Power Resigns from BoardPerk Labs Inc. at its Annual General Meeting of Shareholders held on July 5, 2023, announced Patrick Power has submitted his resignation to the Board. After review and consideration, the Board has accepted Mr. Power's resignation.
공시 • May 25Perk Labs Inc., Annual General Meeting, Jul 05, 2023Perk Labs Inc., Annual General Meeting, Jul 05, 2023.
공시 • Jan 21Perk Labs Inc. Announces CFO TransitionPerk Labs Inc. announced that effective February 17, 2023, Andrew Bailes, a seasoned finance executive, will succeed Ms. Altamirano as Interim CFO until a permanent CFO is named. Vanessa Altamirano will step down effective February 17, 2023 to pursue another professional opportunity. Perk is currently in the process of structuring a merger with Getit Technologies Inc. (‘Getit’), and as part of the process, the Company continues to review its team to optimise the integration of the two companies. Andrew Bailes is a Chartered Public Accountant, Principal at Hertford Advisors and has served in CFO roles since 2006. He has extensive experience in IT, Telecoms, Logistics, manufacturing and other sectors, managing finance and Legal, HR and Operational functions. Andrew did his undergraduate degree in Mathematics and Management Studies at Cambridge University in the UK and was top in his Executive MBA at Cornell and Queens. His notable achievements include: CFO for various capital raises totaling over $100 million Negotiation of many multi-million dollar debt facilities Head of a 25-man Finance Department at one of Ottawa's larger production facilities Twenty-five years' experience in Business and Strategic planning .
공시 • Jan 05Perk Labs Inc. Appoints Patrick Power to the Board of DirectorsPerk Labs Inc. announced that it has appointed Mr. Patrick Power to the company's board of directors, effective immediately. Mr. Power brings a wealth of experience in business and finance to the board. He is the Chairman and President of James Edward Capital Corporation, an Ottawa-based boutique investment bank focused on emerging growth companies and is advising the Company on its strategic options. Mr. Power has significant experience in finance and governance, having previously served in senior executive roles for several TSX/TSXV-listed technology companies.